<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01907490</url>
  </required_header>
  <id_info>
    <org_study_id>Ha03-004</org_study_id>
    <nct_id>NCT01907490</nct_id>
  </id_info>
  <brief_title>Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation</brief_title>
  <official_title>A Safety and Pharmacokinetic Study of Ha44 Gel Administered Topically Under Maximal Use Conditions for the Treatment of Head Lice Infestation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hatchtech Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Accelovance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Target Health Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hatchtech Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and tolerability of a single application
      of Ha44 Gel 0.74% w/v for the treatment of head lice under maximal use conditions.

      Secondary objective is to evaluate pharmacokinetics of Ha44 and benzyl alcohol (contained in
      Ha44 vehicle) under maximal use conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label safety and pharmacokinetic (PK) study involving a single application of
      Ha44 Gel 0.74% administered under maximal use conditions.

      All participants must have an active head lice infestation (at least 3 live lice) and be 6
      months to 17 years of age. The study will enroll approximately 36 pediatric subjects between
      the ages of 6 months and 17 years.

      Pediatric PK samples will be collected at 0 (predose), 30 and 60 mins and 2 and 8 hrs time
      points.

      More than one household member with an active lice infestation may participate in the study.
      Eligible subjects will be consented and screened for study eligibility on Day 0 (Visit 1).
      All subjects will return to the study site for three follow-up clinic visits at Days 1, 7 and
      14. The maximum study duration for a subject is 16 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of the Subjects With AEs.</measure>
    <time_frame>3 months</time_frame>
    <description>Safety and tolerability assessed by AEs. Number of subjects with reporting AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pk Parameters: Cmax</measure>
    <time_frame>3 months</time_frame>
    <description>Pharmacokinetics of Ha44 and Benzyl Alcohol evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: Tmax</measure>
    <time_frame>3 months</time_frame>
    <description>Pharmacokinetics of Ha44 and Benzyl Alcohol evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters: AUC</measure>
    <time_frame>3 months</time_frame>
    <description>Pharmacokinetics of Ha44 and Benzyl Alcohol evaluation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Head Lice Infestation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ha44 Gel 0.74%, topical solution, maximum feasible amount applied for 10 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ha44 Gel</intervention_name>
    <description>Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Benzyl Alcohol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female

          2. 6 months to 17 years of age

          3. Be in good health, as determined by medical history and physical examination

          4. Has an active head lice infestation at screening as determined by an experienced
             evaluator. An active infestation is defined as the presence of at least 3 live lice.

          5. Female subjects must be:

               -  Of non-childbearing potential (no history of menstrual periods,
                  post-hysterectomy, or post-menopausal for at least 2 years) OR,

               -  If of childbearing potential, must have a negative urine pregnancy test prior to
                  treatment and agree to use a highly effective method of contraception from Day 0
                  through the Day 14 visit. Acceptable methods of contraception include abstinence,
                  vasectomized partner, tubal ligation, combined oral hormonal contraceptive,
                  contraceptive injection, contraceptive patch, or IUD. If a hormonal contraception
                  is the only method, the subject must have been on a stable dose for at least 3
                  months.

          6. The parent/guardian agrees to allow serial blood samples collected from subject for PK
             analysis during study.

          7. Has signed an informed consent and/or assent form (ICF).

        Exclusion Criteria:

          1. Has a condition or illness that, in the opinion of the Investigator, may interfere
             with the study results.

          2. Has current dermatological disease or inflammation on the face, scalp, ears, neck or
             back, including eczema, atopic dermatitis, alopecia, psoriasis or any other chronic
             skin disease that, in the opinion of the Investigator, would interfere with the safety
             or PK evaluation.

          3. Had a prior reaction to products containing piperonyl butoxide, pyrethrin, or
             pyrethrum extract.

          4. Has been using hormonal contraception for less than 3 months.

          5. Is pregnant or currently nursing.

          6. Receiving systemic or topical medication, which in the opinion of the Investigator,
             may interfere with the study results.

          7. Has received an investigational agent within 30 days prior to Day 0.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2013</study_first_submitted>
  <study_first_submitted_qc>July 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <results_first_submitted>January 12, 2015</results_first_submitted>
  <results_first_submitted_qc>January 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2015</results_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Topical treatment of Head Lice Infestation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lice Infestations</mesh_term>
    <mesh_term>Parasitic Diseases</mesh_term>
    <mesh_term>Mite Infestations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzyl Alcohol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ha44 Gel 0.74% w/w</title>
          <description>Ha44 Gel 0.74% w/w Open label, one arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ha44 Gel 0.74% w/w</title>
          <description>Ha44 Gel 0.74% w/w Open label, one arm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6months-&lt;12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months- &lt;2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years - &lt;3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3years-&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of the Subjects With AEs.</title>
        <description>Safety and tolerability assessed by AEs. Number of subjects with reporting AEs.</description>
        <time_frame>3 months</time_frame>
        <population>paediatric population, children between ages 6 months to &lt;18 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Ha44 Gel 0.74% w/w</title>
            <description>Ha44 Gel 0.74% w/w Open label, one arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of the Subjects With AEs.</title>
          <description>Safety and tolerability assessed by AEs. Number of subjects with reporting AEs.</description>
          <population>paediatric population, children between ages 6 months to &lt;18 years.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pk Parameters: Cmax</title>
        <description>Pharmacokinetics of Ha44 and Benzyl Alcohol evaluation</description>
        <time_frame>3 months</time_frame>
        <posting_date>08/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameters: Tmax</title>
        <description>Pharmacokinetics of Ha44 and Benzyl Alcohol evaluation</description>
        <time_frame>3 months</time_frame>
        <posting_date>08/2017</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameters: AUC</title>
        <description>Pharmacokinetics of Ha44 and Benzyl Alcohol evaluation</description>
        <time_frame>3 months</time_frame>
        <posting_date>08/2017</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ha44 Gel 0.74% w/w</title>
          <description>Ha44 Gel 0.74% w/w Open label, one arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For any publication or presentation the materials will be provided to the sponsor for approval. Sponsor will be permitted of 90-120 days for a review and shall have right to request modification if the material to be published will jeopardize the intellectual property of the sponsor .</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Manager</name_or_title>
      <organization>Hatchtech Pty Ltd</organization>
      <phone>+61 3 9092 0490</phone>
      <email>tahveninen@hatchtech.com.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

